Show simple item record

dc.contributor.authorCarrero, Ana
dc.contributor.authorBerenguer, Juan
dc.contributor.authorHontañón, Víctor
dc.contributor.authorGuardiola, Josep M
dc.contributor.authorNavarro, Jordi
dc.contributor.authorvon Wichmann, Miguel A
dc.contributor.authorTéllez, María Jesús
dc.contributor.authorQuereda, Carmen
dc.contributor.authorSantos, Ignacio
dc.contributor.authorSanz, José
dc.contributor.authorGalindo, María J
dc.contributor.authorHernández-Quero, José
dc.contributor.authorJimenez-Sousa, Maria Angeles 
dc.contributor.authorPérez-Latorre, Leire
dc.contributor.authorBellón, José M
dc.contributor.authorResino, Salvador 
dc.contributor.authorEsteban, Herminia
dc.contributor.authorMartínez, Esteban
dc.contributor.authorGonzález-García, Juan
dc.date.accessioned2020-09-30T09:44:16Z
dc.date.available2020-09-30T09:44:16Z
dc.date.issued2020-09-15
dc.identifier.citationClin Infect Dis. 2020 Sep 15;ciaa1396.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11087
dc.description.abstractLittle is known about the effects of eradication of HCV on bone mineral density (BMD) and biomarkers of bone remodeling in HIV/HCV coinfected patients. We prospectively assessed standardized BMD (sBMD) at the lumbar spine and femoral neck, World Health Organization (WHO) BMD categories at both sites, and plasma concentrations of soluble receptor activator of nuclear factor-kappaβ ligand (sRANKL), and osteoprotegerin (OPG) at baseline (the date of initiation of anti-HCV therapy) and at 96 weeks. A total of 238 patients were included, median age 49.5 years, 76.5% males, 48.3% with cirrhosis, 98.3% on antiretroviral therapy, median CD4+ cell count 527 cells/mm 3, 86.6% with HIV-1 RNA < 50 copies/mL. The prevalence of osteoporosis at baseline at the lumbar spine (LS) and femoral neck (FN) was 17.6% and 7.2%, respectively. Anti-HCV therapy comprised pegylated interferon and ribavirin (PegIFN-RBV) plus one direct-acting antiviral in 53.4%, PegIFN-RBV in 34.5%, and sofosbuvir/RBV in 12.2%. A total of 145 (60.9%) patients achieved sustained viral response (SVR). No significant effect of SVR was observed on sBMD for the interaction between time and SVR either in the LS (P=0.801) or the FN (P=0.911). Likewise, no significant effect of SVR was observed in plasma levels of sRANKL (P=0.205), OPG (P=0.249), and sRANKL/OPG ratio (P=0.123) for the interaction between time and SVR. No significant correlation was found between fibrosis by transient elastography, and LS and FN sBMD, at baseline, and week 96. SVR was not associated with significant changes in BMD nor biomarkers of bone remodeling in HIV/HCV-coinfected persons.es_ES
dc.description.sponsorshipThis study was supported by Instituto de Salud Carlos III (ISCII), grant numbers PI11/01556, PI14/01094, PI14/01581, and PI14CIII/00011, and by Ministerio de Sanidad, Servicios Sociales e Igualdad, grant number EC11-241. The study was also funded by the RD16/0025/0017, RD16/0025/0018 and RD16CIII/0002/0002 projects as part of the Plan Nacional R + D + I and cofunded by ISCIII-Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER).es_ES
dc.language.isoenges_ES
dc.publisherOxford University Presses_ES
dc.relation.isversionofPostprintes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subject.meshAntiviral Agentses_ES
dc.subject.meshBiomarkers es_ES
dc.subject.meshBonees_ES
dc.subject.meshCoinfection es_ES
dc.subject.meshHIV es_ES
dc.subject.meshHepatitis C es_ES
dc.subject.meshOsteoporosis es_ES
dc.titleEffects of HCV Eradication on Bone mineral density in HIV/HCV Coinfected Patientses_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID32930720es_ES
dc.identifier.doi10.1093/cid/ciaa1396es_ES
dc.contributor.funderMinisterio de Sanidad, Servicios Sociales e Igualdad (España)es_ES
dc.contributor.funderInstituto de Salud Carlos III - ISCIIIes_ES
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)es_ES
dc.description.peerreviewedes_ES
dc.embargo.terms2021-09-15
dc.identifier.e-issn1537-6591es_ES
dc.relation.publisherversionhttps://doi.org/10.1093/cid/ciaa1396es_ES
dc.identifier.journalClinical infectious diseaseses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI11/01556es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14/01094es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14/01581es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14CIII/00011es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/EC11-241es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD16/0025/0017es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD16/0025/0018es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD16CIII/0002/0002es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/embargoedAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional